India, June 4 -- Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio - oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis - IPF and refractory chronic cough - RCC patients, announced the pricing of its previously disclosed underwritten public offering of 17.4 million common shares at $5.75 per share.
The offering is expected to generate gross proceeds of approximately $100 million before underwriting discounts, commissions, and expenses. All shares are being sold by Trevi.
Additionally, Trevi granted underwriters a 30-day option to purchase up to 2.61 million additional shares at the same price, less discounts and commissions. The offering is anticipated to close on ...